After forfeiting two board seats and undertaking a strategic review, AMAG Pharmaceuticals is saying goodbye to its CEO and two of its drugs. But with another med likely being pulled from the market, AMAG’s sudden decision to cut ties with its chief
read moreConfronting generic pricing pressure that put a hard cap on profits, Pfizer’s Upjohn spinoff deal with Mylan allowed both companies to reinvent themselves in the face of stagnant growth. The Pfizer left over after the merger could be a “messy” one, one
read moreProblems, both manufacturing and financial, with an Austrian fill-finish firm has resulted in a partial hold of a trial of Innate Pharma, the French biotech that has a list of development deals with some of the biggest players in pharma.
read moreIan Read may have shed all his responsibilities at Pfizer, but he clearly has no intention of retreating to a quiet retirement. The pharma giant’s former CEO and executive chairman is joining The Carlyle Group’s healthcare team as a deal scout,
read moreBefore it closed the Bristol-Myers Squibb merger, Celgene last year inked a $55 million settlement with plaintiffs and payers over allegations it blocked multiple myeloma drug competition. Now, something has changed. The company backed out of the deal in late
read moreThe product will be officially announced prior to launch. More: Hikma, Arecor set to co-develop new injectable meds Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals